FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015391071> ?p ?o ?g. }

• W3015391071 endingPage "954" @default.
• W3015391071 startingPage "953" @default.
• W3015391071 abstract "We read with great interest the Editorial review by Costiniuk and Jenabian [1] published recently in AIDS and would like to bring additional evidence about the benefits of cannabinoids in people living with HIV (PLWH), including patients with hepatitis C virus (HCV) co-infection. As highlighted in the review, cannabis use was not associated with lower CD4+ count in the French nationwide multicenter ANRS CO13 HEPAVIH cohort of HIV/HCV co-infected patients, after adjustment for baseline CD4+ count and other clinical variables, suggesting that cannabinoids contained in cannabis do not have a negative effect on circulating CD4+ T cells [2]. In another multicenter cohort in Canada, cannabis use was not associated with liver fibrosis or cirrhosis progression among co-infected patients who did not have significant fibrosis or end-stage liver disease at baseline [3]. Similarly, data from the largest US cohort of HIV-infected women showed no significant association between duration or frequency of cannabis use and progression to significant fibrosis among HIV/HCV co-infected women [4]. In France, another study based on data from the ANRS CO13 HEPAVIH cohort showed no significant relationship between cannabis use and liver stiffness (based on transient elastography measures) [5], the latter being associated with increased overall and liver-related mortality in the cohort [6]. Moreover, a systematic review with meta-analysis found no association between cannabis use and liver fibrosis progression among HIV/HCV co-infected patients with chronic liver disease [7]. All of these findings are especially relevant given that liver-related complications are one of the main causes of morbidity and mortality in the HIV/HCV co-infected population [8]. Furthermore, in a previous longitudinal study based on data from the HEPAVIH cohort, cannabis use (whether occasional, regular, or daily) was significantly associated with lower risk of insulin resistance, after adjustment for other correlates and confounders [9]. This result is particularly important given that HIV/HCV co-infected individuals have a higher risk of insulin resistance and diabetes, which in turn increases their risk of liver damage, affecting morbidity and mortality [10]. In addition, this association was confirmed in HCV mono-infected patients participating in the French ANRS CO22 HEPATHER cohort, where cannabis use was independently associated with a lower risk of diabetes [11]. The association found between daily cannabis use and a 36% reduction in the risk of liver steatosis among HIV/HCV co-infected individuals in the ANRS CO13 HEPAVIH cohort (after adjusting for BMI, antiretroviral exposure and hazardous alcohol consumption) [12,13] seems to confirm the beneficial effects of cannabis on the metabolic system in this population. This result reflects those found in the general US population, where cannabis users exhibited lower prevalence of nonalcoholic fatty liver disease, independently of known metabolic risk factors [14,15]. In addition, in another US population-based study, cannabis use was associated with reduced incidence of progressive stages of advanced liver disease – including steatosis, steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma – among patients with abusive alcohol use [16]. Likewise, cannabis use was not identified as a risk factor for overall mortality among PLWH with or without HCV co-infection in both US [17] and French cohorts [18], whereas tobacco smoking was a main predictor of overall mortality risk. Interestingly, a competing risk modelling approach using data from the ANRS CO13 HEPAVIH cohort revealed that regular or daily cannabis use was associated with reduced HCV-related mortality by 72%, independently of tobacco smoking, the latter remaining a significant risk factor [19]. Together with the results reported in Costiniuk and Jenabian's Editorial review [1], these additional data suggest that medical cannabinoids may be of specific benefit to PLWH co-infected with HCV and those who are not. For some patients in these two populations, cannabis use is an act of self-medication. It can help manage HIV-related inflammation and, possibly, lessen the effects of a dysfunctioning endocannabinoid system [20] and its repercussions on other systems, in particular, those leading to metabolic disorders. Although further research on the health effects of cannabis use in PLWH with or without HCV co-infection is needed, improving access to controlled cannabinoid-based therapies and implementing risk reduction interventions to reduce smoking habits and promote a healthier lifestyle constitute priority actions, and have the potential to add years to life and life to years in PLWH with or without HCV co-infection. In conclusion, we share Costiniuk and Jenabian's opinion that clinical investigations are important to evaluate the efficacy and safety of cannabis-based therapies aiming to control morbidity and to reduce mortality in PLWH, particularly among HIV/HCV co-infected individuals, within the wider context of supporting healthcare interventions through innovative public policies. Acknowledgements Our thanks to Jude Sweeney for the English revision and editing of this manuscript. Funding: Part of this work was supported by the French National Agency for Research on Aids and Viral Hepatitis (ANRS: France Recherche Nord & sud Sida-hiv Hépatites), with the participation of Abbott France, Glaxo-Smith-Kline, Roche, Schering-Plough, BMS, Merck-Serono. Conflicts of interest There are no conflicts of interest." @default.
• W3015391071 created "2020-04-17" @default.
• W3015391071 creator A5001041075 @default.
• W3015391071 creator A5007096310 @default.
• W3015391071 creator A5009181226 @default.
• W3015391071 creator A5030725109 @default.
• W3015391071 creator A5044031344 @default.
• W3015391071 creator A5053680286 @default.
• W3015391071 creator A5066601680 @default.
• W3015391071 creator A5085208411 @default.
• W3015391071 date "2020-05-01" @default.
• W3015391071 modified "2023-10-11" @default.
• W3015391071 title "Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection" @default.
• W3015391071 cites W2028623783 @default.
• W3015391071 cites W2120910611 @default.
• W3015391071 cites W2168946357 @default.
• W3015391071 cites W2336568147 @default.
• W3015391071 cites W2400179827 @default.
• W3015391071 cites W2609660872 @default.
• W3015391071 cites W2754090008 @default.
• W3015391071 cites W2757616893 @default.
• W3015391071 cites W2762196570 @default.
• W3015391071 cites W2765390941 @default.
• W3015391071 cites W2793121348 @default.
• W3015391071 cites W2801141370 @default.
• W3015391071 cites W2886046928 @default.
• W3015391071 cites W2895058950 @default.
• W3015391071 cites W2905695289 @default.
• W3015391071 cites W2910806171 @default.
• W3015391071 cites W2913860802 @default.
• W3015391071 cites W2968866180 @default.
• W3015391071 doi "https://doi.org/10.1097/qad.0000000000002480" @default.
• W3015391071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32271254" @default.
• W3015391071 hasPublicationYear "2020" @default.
• W3015391071 type Work @default.
• W3015391071 sameAs 3015391071 @default.
• W3015391071 citedByCount "5" @default.
• W3015391071 countsByYear W30153910712020 @default.
• W3015391071 countsByYear W30153910712021 @default.
• W3015391071 countsByYear W30153910712022 @default.
• W3015391071 crossrefType "journal-article" @default.
• W3015391071 hasAuthorship W3015391071A5001041075 @default.
• W3015391071 hasAuthorship W3015391071A5007096310 @default.
• W3015391071 hasAuthorship W3015391071A5009181226 @default.
• W3015391071 hasAuthorship W3015391071A5030725109 @default.
• W3015391071 hasAuthorship W3015391071A5044031344 @default.
• W3015391071 hasAuthorship W3015391071A5053680286 @default.
• W3015391071 hasAuthorship W3015391071A5066601680 @default.
• W3015391071 hasAuthorship W3015391071A5085208411 @default.
• W3015391071 hasConcept C118552586 @default.
• W3015391071 hasConcept C126322002 @default.
• W3015391071 hasConcept C201903717 @default.
• W3015391071 hasConcept C203014093 @default.
• W3015391071 hasConcept C2522874641 @default.
• W3015391071 hasConcept C2776408679 @default.
• W3015391071 hasConcept C2776455275 @default.
• W3015391071 hasConcept C2777056318 @default.
• W3015391071 hasConcept C2777075537 @default.
• W3015391071 hasConcept C2777214474 @default.
• W3015391071 hasConcept C2778772119 @default.
• W3015391071 hasConcept C2779134260 @default.
• W3015391071 hasConcept C2780826214 @default.
• W3015391071 hasConcept C2994217296 @default.
• W3015391071 hasConcept C71924100 @default.
• W3015391071 hasConcept C72563966 @default.
• W3015391071 hasConceptScore W3015391071C118552586 @default.
• W3015391071 hasConceptScore W3015391071C126322002 @default.
• W3015391071 hasConceptScore W3015391071C201903717 @default.
• W3015391071 hasConceptScore W3015391071C203014093 @default.
• W3015391071 hasConceptScore W3015391071C2522874641 @default.
• W3015391071 hasConceptScore W3015391071C2776408679 @default.
• W3015391071 hasConceptScore W3015391071C2776455275 @default.
• W3015391071 hasConceptScore W3015391071C2777056318 @default.
• W3015391071 hasConceptScore W3015391071C2777075537 @default.
• W3015391071 hasConceptScore W3015391071C2777214474 @default.
• W3015391071 hasConceptScore W3015391071C2778772119 @default.
• W3015391071 hasConceptScore W3015391071C2779134260 @default.
• W3015391071 hasConceptScore W3015391071C2780826214 @default.
• W3015391071 hasConceptScore W3015391071C2994217296 @default.
• W3015391071 hasConceptScore W3015391071C71924100 @default.
• W3015391071 hasConceptScore W3015391071C72563966 @default.
• W3015391071 hasIssue "6" @default.
• W3015391071 hasLocation W30153910711 @default.
• W3015391071 hasOpenAccess W3015391071 @default.
• W3015391071 hasPrimaryLocation W30153910711 @default.
• W3015391071 hasRelatedWork W1486680309 @default.
• W3015391071 hasRelatedWork W1967442145 @default.
• W3015391071 hasRelatedWork W2052723208 @default.
• W3015391071 hasRelatedWork W2057741435 @default.
• W3015391071 hasRelatedWork W2076945923 @default.
• W3015391071 hasRelatedWork W2085723845 @default.
• W3015391071 hasRelatedWork W2569228055 @default.
• W3015391071 hasRelatedWork W3015391071 @default.
• W3015391071 hasRelatedWork W3186377935 @default.
• W3015391071 hasRelatedWork W4243299974 @default.
• W3015391071 hasVolume "34" @default.
• W3015391071 isParatext "false" @default.
• W3015391071 isRetracted "false" @default.

• next